MissionIRNewsBreaks – Sigyn Therapeutics Inc. (SIGY) Announces Publication of Article on Emerging Candidate – Sigyn Therapy(TM)

 Sigyn Therapeutics (OTCQB: SIGY), a development-stage medical technology company, today announced that it has published an article entitled: “Sigyn Therapy(TM), an Emerging Candidate to Address Endotoxemia, Sepsis and Drug-Resistant Viral & Bacterial Infections.” “When we designed Sigyn Therapy, we envisioned a medical device that could overcome the limitations of previous blood purification technologies to treat life-threatening conditions that are beyond the reach of drugs. Along with the efforts of our dedicated team, contributions from science advisors, collaborators and shareholders have helped to advance our vision toward reality,” said Jim Joyce, co-founder and CEO of Sigyn Therapeutics. “Consider that in the midst of the COVID-19 pandemic, we progressed Sigyn Therapy from concept through initial product development and then completed a series of five invitro study programs that validated the ability of Sigyn Therapy to extract twelve relevant therapeutic targets from human blood plasma. Subsequently, we completed first-in-mammal studies at the University of Michigan and then leveraged dialysis industry relationships to establish the treatment protocol, clinical site locations, and principal investigators for first-in-human studies of Sigyn Therapy.”

To view the full press release, visit https://ibn.fm/tyCGz

About Sigyn Therapeutics Inc.

Sigyn Therapeutics is a development-stage, medical-technology company headquartered in San Diego, California. The company’s therapeutic candidates are each designed to overcome a clearly defined limitation in healthcare. These include the ImmunePrep(TM) platform, ChemoPrep(TM), ChemoPure(TM) and Sigyn Therapy(TM). ImmunePrep is a development-stage commercialization platform to enhance and extend the performance of immunotherapeutic antibodies, which account for nine of the top 15 best-selling cancer treatment drugs. ChemoPrep is designed to optimize the delivery of chemotherapy, the most commonly administered drug to treat cancer, while ChemoPure extracts off-target chemotherapy from the bloodstream to reduce patient toxicity. Sigyn Therapy is a novel blood purification technology being advanced to treat pathogen-associated conditions that are not addressed with drug therapies. In vitro studies have demonstrated the ability of Sigyn Therapy to reduce the circulating prevalence of 12 pathogen and inflammatory-disease targets from human blood plasma. Based on these outcomes, candidate treatment indications include drug-resistant viral and bacterial infections, endotoxemia and sepsis, the leading cause of hospital deaths in the United States. First-in-human feasibility studies of Sigyn Therapy plan to enroll end-stage renal disease (“ESRD”) patients with endotoxemia and concurrent inflammation, which are highly prevalent and associated with increased mortality in the ESRD population. For more information, visit the company’s website at www.SigynTherapeutics.com.

NOTE TO INVESTORS: The latest news and updates relating to SIGY are available in the company’s newsroom at https://ibn.fm/SIGY

About MissionIR

MissionIR (“MIR”) is a specialized communications platform with a focus on assisting IR firms with syndicated content to enhance the visibility of private and public companies within the investment community. It is one of 60+ brands within the Dynamic Brand Portfolio @ IBN that delivers: (1) access to a vast network of wire solutions via InvestorWire to efficiently and effectively reach a myriad of target markets, demographics and diverse industries; (2) article and editorial syndication to 5,000+ outlets; (3) enhanced press release enhancement to ensure maximum impact; (4) social media distribution via IBN to millions of social media followers; and (5) a full array of tailored corporate communications solutions. With broad reach and a seasoned team of contributing journalists and writers, MIR is uniquely positioned to best serve private and public companies that want to reach a wide audience of investors, influencers, consumers, journalists and the general public. By cutting through the overload of information in today’s market, MIR brings its clients unparalleled recognition and brand awareness.

MIR is where breaking news, insightful content and actionable information converge.

For more information, please visit www.MissionIR.com

Please see full terms of use and disclaimers on the MissionIR website applicable to all content provided by MIR, wherever published or re-published: https://www.MissionIR.com/Disclaimer

MissionIR
Los Angeles, CA
www.MissionIR.com
310.299.1717 Office
Editor@MissionIR.com

MissionIR is powered by IBN

SenesTech Inc.’s (NASDAQ: SNES) Evolve(TM) Soft Bait – New York’s Answer to the Growing Rat Problem

 

• SenesTech’s Evolve(TM) Soft Bait has been proposed to be used in New York City to control its growing rat population
• In a bill tabled by Upper West Side Council Member Shaun Abreu, the city will explore contraception for rats and will start with a 10-block area
• SenesTech’s CTO notes that the city should see close to complete elimination of the population in 12-18 months, not by just controlling the death rate, but by controlling the birth rate as well
• For SenesTech, this move helps affirm the superiority of its products. In addition, it serves as a sign of even bigger things to come

On Thursday, April 11, Flaco, an escaped zoo owl, was found dead with raised levels of rodenticide in his system in New York City, having consumed poisoned rats for sustenance. This was a wake-up call, highlighting the ineffectiveness of the current approach to controlling the city’s rat population and its cost to pets, wildlife, and birds of prey (https://ibn.fm/aF3pC). As a result, the event prompted involved parties to explore alternative, more effective, and more humane approaches to controlling this rat problem, with contraceptives proving to be the viable option.

SenesTech (NASDAQ: SNES), a rodent fertility control product and service provider, and the inventor of the only EPA-registered contraceptive for male and female rats, has been rapidly growing with its unique rodent control solutions, defined by its two main offerings – ContraPest(R) liquid, and Evolve(TM) Soft Bait, both of which have demonstrated impressive results in controlling pest populations through fertility control. The city of New York is exploring the use of Evolve, owing to its shelf life, safety profile and overall effectiveness.

Studies have shown that two rats alone can multiply to 15,000 in just one year. While poisoning and controlling their death rate has proven ineffective and dangerous for other animals, contraception is showing to be an excellent option to explore, particularly since, for a controlled population, one can achieve complete elimination in 12-18 months.

“If you’ve gotten the whole population on birth control, you should see close to a complete elimination of that population in 12 to 18 months. You’re not controlling the death rate. You’re controlling the birth rate,” noted Dan Palasky, SenesTech’s Chief Technical Officer (https://ibn.fm/PReR4).

With the introduction of a new bill by an Upper West Side Council Member, the city is set to, hopefully once and for all, deal with the rat menace that has posed a challenge for every generation of New Yorkers. Various approaches have been explored, from the hiring of a “rat czar” in 2023 to the push to put trash out in boxes as opposed to bags to reduce the amount of food served up to rats (https://ibn.fm/PjiwW). While it holds true that rodents can never be eradicated, contraception is a viable option in managing their population, all within a reasonable timeline. This is achieved without the risk of poisoning other animals, as was the case with Flaco.

“Rat birth control is a promising non-toxic solution to remediating heavily infested areas without dumping lethal poisons all over our city’s streetscape,” noted Shaun Abreu, an Upper West Side City Council Member.

“We can’t poison our way out of the rat problem, but we can certainly do a lot of damage trying,” he added.

Abreu’s pilot program is proposed to start with a 10-block area, with a six-month study to gain a baseline understanding of rodent populations. This will then be followed by six months of birth control. SenesTech is optimistic that its Evolve Soft Bait will yield impressive results over that period, highlighting the product’s overall efficacy while stamping the company’s position as a leader in its space. Already, the company has seen major interest in its Evolve product, and this move by the city of New York is seen as affirming the product’s superiority while serving as a sign of even bigger things to come.

For more information, visit the company’s website at www.SenesTech.com.

NOTE TO INVESTORS: The latest news and updates relating to SNES are available in the company’s newsroom at https://ibn.fm/SNES

About MissionIR

MissionIR (“MIR”) is a specialized communications platform with a focus on assisting IR firms with syndicated content to enhance the visibility of private and public companies within the investment community. It is one of 60+ brands within the Dynamic Brand Portfolio @ IBN that delivers: (1) access to a vast network of wire solutions via InvestorWire to efficiently and effectively reach a myriad of target markets, demographics and diverse industries; (2) article and editorial syndication to 5,000+ outlets; (3) enhanced press release enhancement to ensure maximum impact; (4) social media distribution via IBN to millions of social media followers; and (5) a full array of tailored corporate communications solutions. With broad reach and a seasoned team of contributing journalists and writers, MIR is uniquely positioned to best serve private and public companies that want to reach a wide audience of investors, influencers, consumers, journalists and the general public. By cutting through the overload of information in today’s market, MIR brings its clients unparalleled recognition and brand awareness.

MIR is where breaking news, insightful content and actionable information converge.

For more information, please visit www.MissionIR.com

Please see full terms of use and disclaimers on the MissionIR website applicable to all content provided by MIR, wherever published or re-published: https://www.MissionIR.com/Disclaimer

MissionIR
Los Angeles, CA
www.MissionIR.com
310.299.1717 Office
Editor@MissionIR.com

MissionIR is powered by IBN

Lexaria Bioscience Corp. (NASDAQ: LEXX) Targeting the Massive Type 2 Diabetes and Obesity Markets with its DehydraTECH(TM) Technology

 

• Lexaria, a global innovator in drug delivery platforms, through its patented DehydraTECH(TM) technology, looks to address the growing type 2 diabetes and obesity problem
• Given the success of previous studies, the company is looking to double down on glucagon-like peptide 1 (“GLP-1”) studies for 2024
• GLP-1 treatments are a major player in managing weight and addressing diabetes, and Lexaria’s DehydraTECH(TM) drug delivery platform has the potential of replacing painful and expensive GLP-1 injections with an effective oral delivery path
• The company has already received independent ethics review board approval for its GLP-1 human pilot study #2, a milestone that brings it closer to offering a tolerable oral delivery option for diabetes treatment

Lexaria Bioscience (NASDAQ: LEXX), a global innovator in drug delivery platforms, recognizes the tremendous potential in the treatment of type 2 diabetes and obesity, and looks to address it through its patented DehydraTECH(TM) drug delivery technology that offers improved delivery of bioactive compounds. The confidence in its technology, as evidenced by the success of previous clinical studies, has allowed it to double down on glucagon-like peptide 1 (“GLP-1”) studies for the 2024 calendar year. The company is optimistic that the studies will yield positive results, not just in the potential treatment of diabetes but also in weight management, which has been directly linked to diabetes.

According to the Centers for Disease Control and Prevention (“CDC”), more than one in three Americans today are at increased risk for type 2 diabetes. This represents about 98 million Americans, with 81% not knowing they are at such a risk (https://ibn.fm/VG8YI). Studies showed a massive spike in overall incidences of type 2 diabetes between 2002 and 2018, with one of the main cited risk factors being obesity. The CDC noted that of those diagnosed with the condition, 89.8% of them were overweight or obese, as defined by a body mass index (“BMI”) of 25 kg/m2 or higher. This was further compounded by physical inactivity, with 31.9% of those diagnosed reporting getting less than 10 minutes a week of moderate or vigorous activity (https://ibn.fm/3Ass4).

In March, Lexaria announced details of its upcoming 12-week animal study WEIGHT-A24-1 that will examine diabetes and weight loss effects of DehydraTECH-processed GLP-1 drugs and DehydraTECH-processed cannabidiol, alone and in combination (https://ibn.fm/TIcIT). Results will guide additional human investigations.

The company recently received independent third-party ethics review board approval for its GLP-1 human pilot study #2, seeking to explore the oral delivery of GLP-1 drugs. For Lexaria, this marks a significant milestone that brings it closer to offering a more effective and tolerable oral delivery option for diabetes treatment and weight loss management (https://ibn.fm/CyRPR).

“Most GLP-1 drugs sold today are administered by painful and expensive injection devices. More effective and tolerable oral delivery of GLP-1 drugs could be extremely valuable to patients and to industry,” noted Chris Bunka, Lexaria’s CEO.

“I am excited about this study; the Lexaria scientific team believes that a dissolvable oral tablet that delivers an effective fraction of semaglutide along with reduced side effects could potentially offer valuable benefits to the pharmaceutical industry that might lead to a higher likelihood of favorable strategic partnering with leading industry players in GLP-1,” he added.

Previous Lexaria studies have demonstrated that DehydraTECH processing results in higher brain absorption than non-DehydraTECH arms. Already, GLP-1R agonists have been shown to penetrate the brain and activate a subset of GLP-1R-expressing neurons in the arcuate nucleus to produce weight loss. With the upcoming studies, Lexaria looks to evidence that DehydraTECH processing of GLP-1 drugs can enable even faster penetration into brain tissue, ultimately improving overall efficiency in weight loss and blood sugar control. Its management is optimistic that it will replicate the success of previous studies and looks forward to kickstarting the undertaking.

For more information, visit the company’s website at www.LexariaBioscience.com.

NOTE TO INVESTORS: The latest news and updates relating to LEXX are available in the company’s newsroom at https://ibn.fm/LEXX

About MissionIR

MissionIR (“MIR”) is a specialized communications platform with a focus on assisting IR firms with syndicated content to enhance the visibility of private and public companies within the investment community. It is one of 60+ brands within the Dynamic Brand Portfolio @ IBN that delivers: (1) access to a vast network of wire solutions via InvestorWire to efficiently and effectively reach a myriad of target markets, demographics and diverse industries; (2) article and editorial syndication to 5,000+ outlets; (3) enhanced press release enhancement to ensure maximum impact; (4) social media distribution via IBN to millions of social media followers; and (5) a full array of tailored corporate communications solutions. With broad reach and a seasoned team of contributing journalists and writers, MIR is uniquely positioned to best serve private and public companies that want to reach a wide audience of investors, influencers, consumers, journalists and the general public. By cutting through the overload of information in today’s market, MIR brings its clients unparalleled recognition and brand awareness.

MIR is where breaking news, insightful content and actionable information converge.

For more information, please visit www.MissionIR.com

Please see full terms of use and disclaimers on the MissionIR website applicable to all content provided by MIR, wherever published or re-published: https://www.MissionIR.com/Disclaimer

MissionIR
Los Angeles, CA
www.MissionIR.com
310.299.1717 Office
Editor@MissionIR.com

MissionIR is powered by IBN

SuperCom Ltd. (NASDAQ: SPCB) Preparing to Deliver on $5 Million in New Sales Orders for European Electronic Monitoring Officials

 

• The growing call for court-administered electronic monitoring services remains, as evidenced by a recent deadly Pacific Northwest domestic violence case in which a judge had previously denied a victim’s petition for requiring the suspect to wear an ankle monitor
• Israel-based SuperCom Ltd. has dedicated its suite of PureSecurity products to help governments economically track and monitor individuals at risk for initiating new dangerous situations
• The company has focused its recent efforts on the North American market, while also making inroads in Europe where it recently received over $5 million in sales orders that it will fulfill over the next few months
• SuperCom’s recently announced financial reports highlight the company’s growing success at building its gross margin, revenues, and profits, including a reported 2,350 percent increase in EBITDA

A series of new orders for electronic monitoring technology to bolster European governments’ security infrastructure is strengthening the position of SuperCom (NASDAQ: SPCB) in the EM market.

The recent sales orders for SuperCom’s PureSecurity Suite of products amount to more than $5 million in revenues, orders that the growing electronic-monitoring (“EM”) security solutions provider expects to fulfill within the next three months.

“We are pleased to continue our collaboration with European government customers, further solidifying our dedication to enhancing public safety through our innovative products and solutions,” SuperCom President and CEO Ordan Trabelsi stated in a news release about the requisitions (https://ibn.fm/hqgCG). “This demonstrates the continued validation of our cutting-edge technology, our steadfast dedication to project delivery, and the invaluable relationships we’ve cultivated with our discerning customers.”

SuperCom is celebrating its growth after recently releasing its financial reports for the Q4 period and the year-end results for 2023. The financial reports showed the company’s gross margin grew to 41.4 percent, its EBITDA grew by 2,350 percent and gross profits rose 60 percent (https://ibn.fm/eycFr).

The company offers an end-to-end electronic monitoring solution with state-of-the-art GPS tracking in real time, secured communication and other monitoring technologies.

The PureProtect and PureOne products, which were rolled out during the year, provide improved protection to families suffering from domestic violence and an all-in-one GPS tracking ankle bracelet monitoring solution. The products have the potential to save lives in a society where domestic conflicts too often turn violent.

A Washington state domestic violence case that gained the attention of Pacific Northwest residents in late April (https://ibn.fm/vBH3L) served as a very recent example of the concerns these cases bring and the need for technological solutions to provide people with protection. Following the kidnapping of a young child and the death of two women, media reports noted one of the victims had sought a court order requiring the suspect to wear an electronic ankle monitor under the provisions of the Tiffany Hill Act, but the court denied the request (https://ibn.fm/erpBj).

SuperCom’s solutions also supports alcohol and drug substance treatment program monitoring, house arrest monitoring, and inmate monitoring. The monitors are easily concealable to reduce concerns about stigmatizing their wearers and include an ultra-lightweight base station with long battery life.

“Since 2018, SuperCom has secured over 50 new multi-year government projects. Our strong growing reputation as a premium provider of electronic monitoring solutions and services enhanced our market position with each new customer win,” Ordan said in a discussion of the year-end financial report (https://ibn.fm/fTjDu).

For more information, visit the company’s website at www.SuperCom.com.

NOTE TO INVESTORS: The latest news and updates relating to SPCB are available in the company’s newsroom at http://ibn.fm/SPCB

About MissionIR

MissionIR (“MIR”) is a specialized communications platform with a focus on assisting IR firms with syndicated content to enhance the visibility of private and public companies within the investment community. It is one of 60+ brands within the Dynamic Brand Portfolio @ IBN that delivers: (1) access to a vast network of wire solutions via InvestorWire to efficiently and effectively reach a myriad of target markets, demographics and diverse industries; (2) article and editorial syndication to 5,000+ outlets; (3) enhanced press release enhancement to ensure maximum impact; (4) social media distribution via IBN to millions of social media followers; and (5) a full array of tailored corporate communications solutions. With broad reach and a seasoned team of contributing journalists and writers, MIR is uniquely positioned to best serve private and public companies that want to reach a wide audience of investors, influencers, consumers, journalists and the general public. By cutting through the overload of information in today’s market, MIR brings its clients unparalleled recognition and brand awareness.

MIR is where breaking news, insightful content and actionable information converge.

For more information, please visit www.MissionIR.com

Please see full terms of use and disclaimers on the MissionIR website applicable to all content provided by MIR, wherever published or re-published: https://www.MissionIR.com/Disclaimer

MissionIR
Los Angeles, CA
www.MissionIR.com
310.299.1717 Office
Editor@MissionIR.com

MissionIR is powered by IBN

MissionIRNewsBreaks – Scinai Immunotherapeutics Ltd. (NASDAQ: SCNI) Announces Nasdaq Delisting Notification and Appeal, ADS Ratio Change

 Scinai Immunotherapeutics (NASDAQ: SCNI) is a biopharmaceutical company focused on developing inflammation and immunology (“I&I”) biological products and providing CDMO services through its Scinai Bioservices business unit. The company today announced that it has received a staff determination letter on April 30, 2024, from the Listing Qualifications Department of the Nasdaq Stock Market LLC. In the letter, Nasdaq notified the company that, due to its non-compliance with the minimum $1.00 bid price requirement set forth in Nasdaq Listing Rule 5550(a)(2), the company’s American Depositary Shares (“ADSs”) would be scheduled for delisting from the Nasdaq Capital Market and would be suspended for trading at the opening of business on May 7, 2024, unless the company timely requests a hearing before an independent Nasdaq Hearings Panel. Scinai appealed the delisting determination and requested a hearing before the panel. In addition, the company also announced that its board of directors has approved a ratio change of the ADSs to its non-traded ordinary shares, increasing the number of ordinary shares represented by each ADS from 400 to 4,000, which is equivalent to a reverse split of 1 for 10. No action is required by the holders of the ADSs to affect the ratio change, and no fractional new ADSs will be issued in connection with the change in ADS ratio.

To view the full press release, visit https://ibn.fm/Tu3AA

About Scinai Immunotherapeutics Ltd.

Scinai is a biopharmaceutical company with two complementary business units. One is focused on in-house development of inflammation and immunology (“I&I”) biological therapeutic products beginning with an innovative, de-risked pipeline of nanosized VHH antibodies (“NanoAbs”) targeting diseases with large unmet medical needs. The second business unit is a boutique CDMO providing biological drug development, analytical methods development, clinical GMP manufacturing, and pre-clinical and clinical trial design and execution services to early-stage biotech companies. For more information, visit the company’s website at www.Scinai.com.

NOTE TO INVESTORS: The latest news and updates relating to SCNI are available in the company’s newsroom at https://ibn.fm/SCNI

About MissionIR

MissionIR (“MIR”) is a specialized communications platform with a focus on assisting IR firms with syndicated content to enhance the visibility of private and public companies within the investment community. It is one of 60+ brands within the Dynamic Brand Portfolio @ IBN that delivers: (1) access to a vast network of wire solutions via InvestorWire to efficiently and effectively reach a myriad of target markets, demographics and diverse industries; (2) article and editorial syndication to 5,000+ outlets; (3) enhanced press release enhancement to ensure maximum impact; (4) social media distribution via IBN to millions of social media followers; and (5) a full array of tailored corporate communications solutions. With broad reach and a seasoned team of contributing journalists and writers, MIR is uniquely positioned to best serve private and public companies that want to reach a wide audience of investors, influencers, consumers, journalists and the general public. By cutting through the overload of information in today’s market, MIR brings its clients unparalleled recognition and brand awareness.

MIR is where breaking news, insightful content and actionable information converge.

For more information, please visit www.MissionIR.com

Please see full terms of use and disclaimers on the MissionIR website applicable to all content provided by MIR, wherever published or re-published: https://www.MissionIR.com/Disclaimer

MissionIR
Los Angeles, CA
www.MissionIR.com
310.299.1717 Office
Editor@MissionIR.com

MissionIR is powered by IBN